Yeah, I should've been more clear on that. My frustration isn't with the blogger, it's with the company. If you remember, there was an article by I believe Newsweek recently that focused largely on the ethical dilemma of the use of embryonic stem cells and featured ACTC's upcoming trials but NOWHERE during the interviews with Lanza did he ever even mention the single-blastomere technology. Management definitely doesn't do a good job getting the complete story about the company out there. They've had some great opportunities and have repeatedly failed in this regard.
News 
Market Data 
Discover 
AI
